KLTO
Klotho Neurosciences, Inc.
Biotechnology
Market Cap$7M
5Y Perf.-59.1%
Build Your Comparison
Side-by-side financial analysisKLTO
PRAX
Try popular comparisons:
Stock Comparison
KLTO vs PRAX
Revenue, margins, valuation, and 5-year total return — side by side.
PRAX
Praxis Precision Medicines, Inc.
Biotechnology
Market Cap$7.70B
5Y Perf.+533.6%
KLTO vs PRAX — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot |  KLTO |  PRAX |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $7M | $7.70B |
| Revenue (TTM) | $0.00 | $0.00 |
| Net Income (TTM) | $-11M | $-327M |
| Total Debt | $272K | $110K |
| Cash & Equiv. | $64K | $357M |
KLTO vs PRAX — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
KLTO
PRAX
| Stock | Aug 24 | Mar 26 | Return |
|---|---|---|---|
| Klotho Neuroscience… (KLTO) | 100 | 40.9 | -59.1% |
| Praxis Precision Me… (PRAX) | 100 | 633.6 | +533.6% |
Price return only. Dividends and distributions are not included.
Quick Verdict: KLTO vs PRAX
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: PRAX leads in 5 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. As sector peers, any of these can serve as alternatives in the same allocation.
🥇PRAX emerged as the overall leader. Track its performance:
KLTO
Klotho Neurosciences, Inc.
The Specific-Use Pick
In this particular matchup, KLTO is outpaced on most metrics by others in the set.
Best for: healthcare exposure
PRAX
Praxis Precision Medicines, Inc.
The Income Pick
PRAX carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 1.55
- Rev growth -100.0%, EPS growth -32.0%
- -36.1% 10Y total return vs KLTO's -63.0%
Best for: income & stability and growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth |  PRAX | -100.0% revenue growth vs KLTO's -49.0% |
| Quality / Margins | PRAX | 2.4% margin vs KLTO's -14.5% |
| Stability / Safety | PRAX | Beta 1.55 vs KLTO's 1.91, lower leverage |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | PRAX | +491.9% vs KLTO's -81.0% |
| Efficiency (ROA) | PRAX | -40.2% ROA vs KLTO's -112.1%, ROIC -65.0% vs -242.3% |
KLTO vs PRAX — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2024
KLTO vs PRAX — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLPRAXLAGGINGKLTO
KLTOKlotho Neurosciences,…
1leads
PRAXPraxis Precision Medi…
3leads
6 Total Categories
CATEGORYLEADERvs KLTOMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
KLTO1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
PRAX7/8
Total Returns1Y, 3Y, 5Y total returns with dividends
PRAX5/6
Risk & VolatilityBeta, volatility, and downside exposure
PRAX2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
KLTO leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
KLTO and PRAX operate at a comparable scale, with $0 and $0 in trailing revenue.
| Metric | KLTOKlotho Neuroscien… | PRAXPraxis Precision … |
|---|---|---|
| RevenueTrailing 12 months | $0 | $0 |
| EBITDAEarnings before interest/tax | -$8M | -$357M |
| Net IncomeAfter-tax profit | -$11M | -$327M |
| Free Cash FlowCash after capex | -$6M | -$283M |
| Gross MarginGross profit ÷ Revenue | — | — |
| Operating MarginEBIT ÷ Revenue | — | — |
| Net MarginNet income ÷ Revenue | — | — |
| FCF MarginFCF ÷ Revenue | — | — |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | +72.9% | +2.7% |
KLTO leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — KLTO and PRAX each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | KLTOKlotho Neuroscien… | PRAXPraxis Precision … |
|---|---|---|
| Market CapShares × price | $7M | $7.7B |
| Enterprise ValueMkt cap + debt − cash | $8M | $7.3B |
| Trailing P/EPrice ÷ TTM EPS | -1.19x | -19.77x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | — |
| Price / BookPrice ÷ Book value/share | 6.19x | 6.83x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — KLTO and PRAX each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
PRAX leads this category, winning 7 of 8 comparable metrics.
Profitability & Efficiency
PRAX delivers a -43.0% return on equity — every $100 of shareholder capital generates $-43 in annual profit, vs $-114 for KLTO. PRAX carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to KLTO's 0.23x. On the Piotroski fundamental quality scale (0–9), KLTO scores 4/9 vs PRAX's 3/9, reflecting mixed financial health.
| Metric | KLTOKlotho Neuroscien… | PRAXPraxis Precision … |
|---|---|---|
| ROE (TTM)Return on equity | -113.7% | -43.0% |
| ROA (TTM)Return on assets | -112.1% | -40.2% |
| ROICReturn on invested capital | -2.4% | -65.0% |
| ROCEReturn on capital employed | -6.2% | -49.3% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 3 |
| Debt / EquityFinancial leverage | 0.23x | 0.00x |
| Net DebtTotal debt minus cash | $208,012 | -$357M |
| Cash & Equiv.Liquid assets | $63,741 | $357M |
| Total DebtShort + long-term debt | $271,753 | $110,000 |
| Interest CoverageEBIT ÷ Interest expense | -1.98x | — |
PRAX leads this category, winning 7 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
PRAX leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in PRAX five years ago would be worth $8,580 today (with dividends reinvested), compared to $3,699 for KLTO. Over the past 12 months, PRAX leads with a +491.9% total return vs KLTO's -81.0%. The 3-year compound annual growth rate (CAGR) favors PRAX at 164.8% vs KLTO's -28.2% — a key indicator of consistent wealth creation.
| Metric | KLTOKlotho Neuroscien… | PRAXPraxis Precision … |
|---|---|---|
| YTD ReturnYear-to-date | +19.1% | -6.9% |
| 1-Year ReturnPast 12 months | -81.0% | +491.9% |
| 3-Year ReturnCumulative with dividends | -63.0% | +1757.4% |
| 5-Year ReturnCumulative with dividends | -63.0% | -14.2% |
| 10-Year ReturnCumulative with dividends | -63.0% | -36.1% |
| CAGR (3Y)Annualised 3-year return | -28.2% | +164.8% |
PRAX leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
PRAX leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
PRAX is the less volatile stock with a 1.55 beta — it tends to amplify market swings less than KLTO's 1.91 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. PRAX currently trades 72.7% from its 52-week high vs KLTO's 15.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | KLTOKlotho Neuroscien… | PRAXPraxis Precision … |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.91x | 1.55x |
| 52-Week HighHighest price in past year | $2.45 | $366.52 |
| 52-Week LowLowest price in past year | $0.21 | $37.19 |
| % of 52W HighCurrent price vs 52-week peak | +15.6% | +72.7% |
| RSI (14)Momentum oscillator 0–100 | 61.9 | 31.9 |
| Avg Volume (50D)Average daily shares traded | 95K | 396K |
PRAX leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | KLTOKlotho Neuroscien… | PRAXPraxis Precision … |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $607.15 |
| # AnalystsCovering analysts | — | 16 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +1.6% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
PRAX leads in 3 of 6 categories (Profitability & Efficiency, Total Returns). KLTO leads in 1 (Income & Cash Flow). 1 tied.
Best OverallPraxis Precision Medicines,… (PRAX)Leads 3 of 6 categories
Loading custom metrics...
KLTO vs PRAX: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Is KLTO or PRAX a better buy right now?
Analysts rate Praxis Precision Medicines, Inc.
(PRAX) a "Buy" — based on 16 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — KLTO or PRAX?
Over the past 5 years, Praxis Precision Medicines, Inc.
(PRAX) delivered a total return of -14. 2%, compared to -63. 0% for Klotho Neurosciences, Inc. (KLTO). Over 10 years, the gap is even starker: PRAX returned -36. 1% versus KLTO's -63. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — KLTO or PRAX?
By beta (market sensitivity over 5 years), Praxis Precision Medicines, Inc.
(PRAX) is the lower-risk stock at 1. 55β versus Klotho Neurosciences, Inc. 's 1. 91β — meaning KLTO is approximately 23% more volatile than PRAX relative to the S&P 500. On balance sheet safety, Praxis Precision Medicines, Inc. (PRAX) carries a lower debt/equity ratio of 0% versus 23% for Klotho Neurosciences, Inc. — giving it more financial flexibility in a downturn.
04Which has better profit margins — KLTO or PRAX?
Klotho Neurosciences, Inc.
(KLTO) is the more profitable company, earning 0. 0% net margin versus 0. 0% for Praxis Precision Medicines, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: KLTO leads at 0. 0% versus 0. 0% for PRAX. At the gross margin level — before operating expenses — KLTO leads at 0. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — KLTO or PRAX?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
06Is KLTO or PRAX better for a retirement portfolio?
For long-horizon retirement investors, Praxis Precision Medicines, Inc.
(PRAX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Klotho Neurosciences, Inc. (KLTO) carries a higher beta of 1. 91 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (PRAX: -36. 1%, KLTO: -63. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between KLTO and PRAX?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.